Growth of French life sciences industry set to slow, warns France Biotech
France Biotech, the French association of life science companies and their partners, has published the third edition of its annual Drug Pipeline Review which, although positive on the sector's achievements, foresees difficulties ahead. The survey was part-funded by the French Ministry of the Economy, Industry and Finance.
Commenting on the situation, Philippe Pouletty, chairman of France Biotech, said: "the dynamic growth of France's life science industry - as revealed by the increasing number of very innovative products in the pipeline - may well slacken off. In fact, with a 79% drop in investment in 2008, our innovative SMEs [small- and medium-sized enterprises] are going to have trouble funding all their drug development programs because the latter are very resource-intensive."
Big fall in funding continues
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze